Academic literature on the topic 'Silymarin/ Silibinin'

The present study assessed comparatively the antioxidant activities of silymarin and its major active component silibinin and their neuroprotective effects against hydrogen peroxide (H2O2)-induced oxidative stress in rat pheochromocytoma PC12 cells. It was found that despite newly prepared silymarin and silibinin solution possessing comparable superoxide anion (O2.–)-scavenging activities, with time the activity of silymarin lowered slightly, but that of silibinin decreased dramatically. Both silymarin and silibinin suppressed H2O2-induced oxidative stress and apoptosis, and the neuroprotective effect of silymarin was overall relatively stronger than that of silibinin. The findings provided clues for future studies on therapeutic potentials of the whole silymarin or purified silibinin for neurodegenerative diseases.

Silymarin is a standardized extract from the dried seeds of the milk thistle (Silybum marianumL. Gaertn.) clinically used as an antihepatotoxic agent. The aim of this study was to investigate the antibacterial and antifungal activity of silymarin and its major constituent (silibinin) against different microbial strains and their modulatory effect on drugs utilized in clinical practice. Silymarin demonstrated antimicrobial activity of little significance against the bacterial strains tested, with MIC (minimum inhibitory concentration) values of 512 µg/mL. Meanwhile, silibinin showed significant activity againstEscherichia coliwith a MIC of 64 µg/mL. The results for the antifungal activity of silymarin and silibinin demonstrated a MIC of 1024 µg/mL for all strains. Silymarin and silibinin appear to have promising potential, showing synergistic properties when combined with antibacterial drugs, which should prompt further studies along this line.

ABSTRACT. Purpose: To evaluate the pharmacokinetic interaction between oltipraz and silymarin after intravenous and oral administration of both drugs to male Sprague–Dawley rats. Methods: Oltipraz (single doses of 10 and 30 mg/kg for intravenous and oral administration, respectively), silymarin (single doses of 50 and 100 mg/kg for intravenous and oral administration, respectively, and 14 days oral administration of 100 mg/kg), alone and together were administered to control rats. Results: The pharmacokinetic parameters of oltipraz did not significantly altered by silymarin. However, after intravenous administration of the drugs together, the AUCs of unconjugated, conjugated, and total (unconjugated plus conjugated) silibinin were significantly different (32.7% decrease, and 32.1% and 27.2% increase, respectively), and total and (CL) and non-renal (CLNR ) clearance of unconjugated silibinin were significantly faster (49.4% and 61.1% increase, respectively) than those of silymarin alone (without oltipraz). After oral administration of silymarin with or without oltipraz, however, the pharmacokinetic parameters of unconjugated, conjugated, and total silibinin were comparable. Conclusions: After single intravenous administration of the drugs together, the AUC of unconjugated silibinin was significantly smaller, but that of both conjugated and total silibinin was significantly greater. This could have been due to an increase in the formation of conjugates (glucuronidation and sulfation) of silibinin as induced by oltipraz. After simultaneous oral administration of the drugs, however, the AUCs (or AUC0−12 h) of unconjugated, conjugated, and total silibinin were comparable.

Ferroptosis is involved in various tissue injuries including neurodegeneration, ischemia-reperfusion injury, and acute liver injury. Ferroptosis inhibitors exhibit promising clinical potential in the treatment of various diseases. As a traditional chemical, silymarin has been widely used in healthcare and clinical applications to treat liver injuries in which ferroptosis is involved. Silibinin is the main active ingredient of silymarin. However, the effect of silibinin on ferroptosis and ferroptosis-related diseases remains unclear. Here, we found that silibinin inhibited death in different kinds of cells caused by ferroptosis inducers including RSL3 and erastin. Moreover, silibinin alleviated lipid peroxidation induced by RSL3 without affecting the labile iron pool. Next, the antioxidant activity of silibinin was demonstrated by the DPPH assay. In vivo, silibinin strikingly relieved tissue injuries and ferroptosis in the liver and kidney of glutathione peroxidase 4 (GPX4) knockout C57 BL/6J mice. Moreover, silibinin effectively rescued renal ischemia-reperfusion, a well-known ferroptosis-related disease. In conclusion, our study revealed that silibinin effectively inhibits cell ferroptosis and ferroptosis-related tissue injuries, implicating silibinin as a potential chemical to treat ferroptosis-related diseases.

Silibinin/silymarin has been used in herbal medicine for thousands of years and it is well-known for its hepato-protective properties. The present comprehensive literature review aimed to critically summarize the pharmacological properties of silymarin extract and its main ingredient silibinin in relation to classical cardiovascular risk factors (e.g., diabetes mellitus, etc.). We also assessed their potential protective and/or therapeutic application in cardiovascular diseases (CVDs), based on experimental and clinical studies. Pre-clinical studies including in vitro tests or animal models have predominantly implicated the following effects of silymarin and its constituents: (1) antioxidant, (2) hypolipidemic, (3) hypoglycemic, (4) anti-hypertensive and (5) cardioprotective. On the other hand, a direct amelioration of atherosclerosis and endothelial dysfunction after silymarin administration seems weak based on scarce data. In clinical trials, the most important findings are improved (1) glycemic and (2) lipid profiles in patients with type 2 diabetes mellitus and/or hyperlipidemia, while (3) the anti-hypertensive effects of silibinin/silymarin seem very modest. Finally, the changes in clinical endpoints are not robust enough to draw a firm conclusion. There are significant limitations in clinical trial design, including the great variety in doses and cohorts, the underlying conditions, the small sample sizes, the short duration and the absence of pharmacokinetic/pharmacodynamic tests prior to study commitment. More data from well-designed and high-quality pre-clinical and clinical studies are required to firmly establish the clinical efficacy of silibinin/silymarin and its possible therapeutic application in cardiovascular diseases.

Silymarin is a bioflavonoid complex extract derived from dry seeds of Milk thistle [( Silybum marianum(L.) Gaernt. (Fam. Asteraceae/Compositaceae)] whose hepatoprotective effect has clinically been proved. Low toxicity, favorable pharmacokinetics, powerful antioxidant, detoxifying, preventive, protective and regenerative effects and side effects similar to placebo make silymarin extremely attractive and safe for therapeutic use. The medicinal properties of silymarin and its main component silibinin have been studied in the treatment of Alzheimer's disease, Parkinson's disease, sepsis, burns, osteoporosis, diabetes, cholestasis and hypercholesterolemia. Owing to its apoptotic effect, without cytotoxic effects, silymarin possesses potential applications in the treatment of various cancers. Silymarin is being examined as a neuro-, nephro- and cardio-protective in the damage of different etiologies due to its strong antioxidant potentials. Furthermore, it has fetoprotective (against the influence of alcohol) and prolactin effects and is safe to be used during pregnancy and lactation. Finally, the cosmetics industry is examining the antioxidant and UV-protective effects of silymarin. Further clinical studies and scientific evidence that silymarin and silibinin are effective in the therapy of various pathologies are indispensable in order to confirm their different flavonolignan pharmacological effects.

The Asteraceae family's <em>Silybum marinum</em> plant, commonly known as thistle, yields silymarin in its seeds. A frequently employed hepato-protective treatment for conditions like cirrhosis, fatty liver due to alcohol and hazardous chemicals, and hepatitis is silymarin. Conventional milk thistle extract is derived from seeds containing a silymarin content of 4-6%. The extract has 20&ndash;35% fatty acids, including linoleic acid, and 65&ndash;80% silymarin (a flavonolignan complex). Silymarin constitutes a complex blend of polyphenolic compounds that also contains a flavonoid (taxifolin) and seven closely related flavonolignans (silybin A, silybin B, isosilybin A, isosilybin B, silychristin, silychristin, and silydianin). The two main diastereoisomers of silymarin, silybin A and silybin B, are approximately equally mixed in silibinin, a semi-purified fraction of silymarin. The impact of silymarin on liver, pancreatic, prostate, and skin cancers has been the subject of numerous patents. Owing to silymarin's antioxidant and anti-inflammatory properties, and its ability to modulate various proteins and genes, silymarin exhibits antichemopreventive effects. Moreover, silymarin mitigates the damaging effects on healthy cells or organs. Consequently, silymarin holds potential as an adjuvant therapy for cancer. In this study, the cytotoxicity of silymarin extracts obtained via the HPLC technique&mdash;known for its sensitivity, utility, and established efficacy in determining silymarin quantity from the <em>Silybum marianum</em> plant&mdash;was assessed using a colorimetric test on A-549 cells. It was found that 100 &micro;M was the LD50 when silymarin was administered to A-549 cells in dosages of 25, 50, 75, and 100 &micro;M.

A schematic of a new synthesized nanopolymer (CGONP) and its use as a drug delivery system of silibinin and silymarin extract in the olfactory ensheathing cells (OECs) of rats in normal and high-glucose conditions.

The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a chemopreventive and therapeutic agent in human lung cancer, including translational insights into its mechanism of action to control the aggressive behavior of lung carcinoma subtypes prone to metastasis. First, we summarize the evidence from chemically induced primary lung tumors supporting a role for silibinin in lung cancer prevention. Second, we reassess the preclinical and clinical evidence on the effectiveness of silibinin against drug resistance and brain metastasis traits of lung carcinomas. Third, we revisit the transcription factor STAT3 as a central tumor-cell intrinsic and microenvironmental target of silibinin in primary lung tumors and brain metastasis. Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., KRAS/STK11 co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules.

Objectives: Multiple sclerosis (MS) is a long-lasting demyelinating inflammatory disease of the central nervous system (CNS). It has been shown that brain tissue in MS is exposed to oxidative stress during the disease period. Silymarin, a plant-derived flavonoid, can be extracted from Silybum marianum. The current experiment aimed to explore the effects of silibinin and especially nano-silibinin on neurobehavioral activity and biochemical antioxidant parameters in the cuprizone model of demyelination in mice for the first time. Methods: Demyelination was induced in mice by oral consumption of cuprizone 0.4%w/w for one week and then 0.2%w/w for four weeks. Treatment was performed with silibinin or nano-silibinin (70mg/kg body weight) for four weeks at the same time with cuprizone 0.2%w/w. After neurobehavioral tests (rotarod, tail flick, and open field), biochemical antioxidant parameters (glutathione level, superoxide dismutase activity, lipid peroxidation products, and total antioxidant capacity) were evaluated. Results: In this experiment, behavioral tests (rotarod and open field) displayed improvement in movement dysfunction using silibinin or nano-silibinin. Furthermore, silibinin and more efficiently nano-silibinin increased antioxidant parameters, such as superoxide dismutase (SOD) and glutathione (GSH) and total antioxidant capacity (TAC), and decreased lipid peroxidation. Conclusion: These data suggest that silibinin and nano-silibinin can improve movements in the cuprizone model of demyelination. Moreover, they may prevent cuprizone-induced oxidative stress. In conclusion, silibinin and more effectively, nano-silibinin, may exhibit therapeutic features in MS disease.

Submitted by Cláudia Bueno (claudiamoura18@gmail.com) on 2016-02-04T10:23:14Z No. of bitstreams: 2 Tese - Flavio Fernandes Veloso Borges - 2015.pdf: 2110689 bytes, checksum: 595ebd21ecf4f13568b0e3179e801f99 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)<br>Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-02-04T10:43:08Z (GMT) No. of bitstreams: 2 Tese - Flavio Fernandes Veloso Borges - 2015.pdf: 2110689 bytes, checksum: 595ebd21ecf4f13568b0e3179e801f99 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)<br>Made available in DSpace on 2016-02-04T10:43:08Z (GMT). No. of bitstreams: 2 Tese - Flavio Fernandes Veloso Borges - 2015.pdf: 2110689 bytes, checksum: 595ebd21ecf4f13568b0e3179e801f99 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2015-03-26<br>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES<br>Silymarin (SM) is a standardized extract from the seeds and leaves of milk thistle Silybum marianum (L.) Gaertn. It is composed mainly of flavonolignans, with silibinin (SB) being its principal active constituent. Known mainly as antioxidant and hepatoprotector, SM and SB were found to be clinically effective in the treatment of a variety of liver disorders, including acute and chronic viral hepatitis, toxin and drug-induced hepatitis and cirrhosis. Due to the wide biological activities presented by SM and SB, the present study aimed to evaluate their antimutagenic activities using the Ames mutagenicity test in Salmonella typhimurium, their antigenotoxic activities using the mouse bone marrow micronucleous test and the alkaline comet assay, and to assess their effect on the gene expression pattern of some genes associated with the process of carcinogenesis and chemoprevention. To assess antimutagenicity, bacterial suspensions of Salmonella typhimurium (TA98 and TA100 strains) were treated with different concentrations of SM or SB simultaneously with the appropriate positive controls for each strain. To assess antigenotoxicity, Swiss mice were orally treated with different concentrations of SM or SB simultaneously with a single intraperitoneal dose of mitomycin C (MMC) for the micronucleus test, and human blood lymphocytes were cotreated with SM or SB and methyl methanesulfonate (MMS) for the alcaline comet assay. To investigate the role of SM and SB in modulating gene expression, we conducted microarray analysis. The results showed that SM was not significantly effective in reducing the number of frameshift mutations in strain TA98, while SB demonstrated significant protection at higher doses (p < 0.05). Regarding strain TA 100, SM and SB significantly decreased mutagenicity (point mutations) (p < 0.05). The results of the antigenotoxic evaluation demonstrated that SM and SB significantly reduced the frequency of micronucleated polychromatic erythrocytes (MNPCE) (p < 0.05). The results also indicated that SM and SB significantly attenuated MMC induced cytotoxicity (p < 0.05). In the comet assay, SM and SB significantly reduced the genotoxicity of MMS (p < 0.05), with a stronger antigenotoxic activity exerted by the extract complex (SM) than the one exerted by the isolated main active constituent (SB). The expression array analysis of five genes related to DNA damage, carcinogenesis and/or chemoprevention mechanisms demonstrated an up-regulation of PTEN and BCL2, down-regulation of BAX and ABL1 and no significant change in ETV6 expression levels.In conclusion, our results demonstrated that both SM and SB presented antimutagenic and antigenotoxic actions, as well as modulated the expression levels of genes analysed under the experimental conditions of this study.<br>A silimarina (SM) é um extrato padronizado obtido a partir das sementes e folhas de Silybum marianum (L.) Gaertn. SM é composta principalmente de flavonóides, sendo a silibinina (SB) seu principal componente ativo. Conhecidas principalmente como antioxidantes e hepatoprotetoras, SM e SB foram consideradas clinicamente eficazes no tratamento de uma variedade de doenças do fígado, incluindo hepatites virais agudas e crônicas, hepatites induzidas por toxinas e/ou drogas e cirrose. Assim, devido à ampla gama de atividades biológicas apresentadas pela SM e SB, o presente estudo teve como objetivo avaliar suas atividades antimutagênicas utilizando o teste de Ames em Salmonella typhimurium, suas atividades antigenotóxicas pelo teste do micronúcleo em medula óssea de camundongos e pelo teste do cometa em linfócitos humanos e avaliar seus efeitos nos perfis de expressão gênica de alguns genes associados ao processo de carcinogênese e quimioprevenção. Para a avaliação da antimutagenicidade, suspensões bacterianas de Salmonella typhimurium (cepas TA98 e TA100) foram co-tratadas com diferentes concentrações de SM ou SB e os controles positivos adequados para cada cepa. Para a avaliação de antigenotoxidade, camundongos Swiss foram tratados oralmente com diferentes concentrações de SM ou SB concomitantemente a uma única dose intraperitoneal de mitomicina C (MMC) para o teste do micronúcleo, e linfócitos humanos foram tratados simultaneamente com SM ou SB e metil-metanossulfonato (MMS) para o ensaio do Cometa. Os resultados mostraram que a SM não foi significativamente efetiva em reduzir o número de mutações com deslocamento de quadro de leitura na cepa TA 98, enquanto que a SB apresentou uma proteção significativa nas doses maiores (p < 0.05). Em relação à cepa TA100, SM e SB reduziram significativamente a mutagenicidade (mudanças de pares de bases) (p < 0.05). Na avaliação de antigenotoxidade, SM e SB reduziram significativamente a frequência de eritrócitos policromáticos micronucleados (EPCMN) (p<0,05). Os resultados também mostraram que a citotoxicidade causada pela MMC foi significativamente atenuada pela SM e SB (p<0,05). No ensaio do cometa, SM e SB reduziram significativamente a genotoxicidade provocada pelo MMS (p<0.05), com uma atividade antigenotóxica maior exercida pelo extrato complexo (SM) do que pelo principal componente ativo isolado (SB). A análise dos níveis de expressão de cinco genes relacionados ao dano no DNA, mecanismos de carcinogênese e/ou quimioprevenção demonstrou um aumento na expressão de PTEN e BCL2, diminuição na expressão de BAX e ABL1 e ausência de mudança significativa nos níveis de expressão do ETV6. Com base nesses resultados, conclui-se que a SM e a SB apresentaram ações antimutagênicas e antigenotóxicas, e também modularam os níveis de expressão dos genes analisados sob as condições experimentais deste estudo.

Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2008.<br>Typescript. Includes bibliographical references (leaves 144-170). Free to UCD Anschutz Medical Campus. Online version available via ProQuest Digital Dissertations;

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior<br>The Silymarin is a flavonolignan complex isolated from milk thistle seeds of Silybum marianum being used in the treatment of injury related to oxidative stress, including liver and neurological diseases, as Parkinson disease. Although silymarin has been reported to possess a variety of pharmacological properties including anti-inflammatory, anticarcinogenic and neuroprotective effects, information regard its antimicrobial and drug modulator potential against microbial resistance is scanty in the literature. In addition, the possible involvement of antioxidant activity in its neuroprotective effect, and on the activity of important enzymes of the central nervous system (i.e., Na+/K+-ATPase and monoamine oxidase (MAO)) have not yet been completely elucidated. Therefore, the objective of this study was to investigate the effect of silymarin on the activity of the enzymes Na+/K+-ATPase and MAO as well as its ability in to modulate the action of antimicrobials in vitro. The results demonstrated that silymarin scavenged the DPPH (2,2-diphenyl-1-picrylhydrazyl) radical and, also reduced significantly the Fe2+ (10 μM) and SNP (sodium nitroprusside, 5 μM) induced lipid peroxidation in rat brain homogenate. Silymarin protected against the oxidation of thiol groups (protein and non-protein) induced by the pro-oxidants, and avoided the reduction in the activity of catalase caused by pro-oxidants at a concentration of 30 μg/mL. The incubation of different concentrations of silymarin increased the activity of Na+/K+-ATPase enzyme and reduced the activity of the enzymes MAO-A and MAO-B. However, the inhibition of MAO-B was more pronounced. The evaluation of the kinetic parameters demonstrated that Silymarin did not alter significantly the Km values for MAO-A and MAO-B, but caused a decrease in Vmax values for both isoforms of the enzyme. With regard to the antimicrobial activity, silymarin and its major active constituent silybin, did not demonstrate antibacterial and antifungal activities not relevant from a clinical point of view (with values of MIC - minimal inhibitory concentration- > 500 μg/mL). However, silybin showed clinically significant antibacterial activity against Escherichia coli with MIC/8 = 64 μg/mL. The combination of sylimarin and silybin demonstrated synergistic activity modulating the efficacy of antibiotics drugs (amikacin, gentamicin, ciprofloxaxin ou imipenem) or antifungal (mebendazole ou nystatin), particularly from the class of aminoglycosides, against multiresistant strains Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. However, silybin antagonized the antibacterial effect of gentamicin and imipenem against P. aeruginosa. Similarly, silymarin and silybin had antagonistic effect with nystatin against Candida albicans, Candida tropicalis and Candida kruzei. In conclusion, the results showed that silymarin alters the activities of Na+/K+-ATPase and monoamine oxidase, indicating that its neuroprotective effect is not only associated to its antioxidant capacity. The potential of silymarin and silybin to modulate the effects of the drugs suggests an alternative to control bacterial infections caused by antibiotics resistance.<br>A Silimarina é um complexo de flavonolignanas isolado das sementes de Silybum marianum, sendo utilizada no tratamento de distúrbios relacionados ao estresse oxidativo, incluindo hepatopatias e doenças neurológicas, como a Doença de Parkinson. Embora a silimarina seja referida por possuir uma variedade de propriedades farmacológicas, incluindo efeitos anti-inflamatório, anticancerígeno e neuroprotetor, informações sobre o seu potencial antimicrobiano e modulador de fármacos contra a resistência microbiana são escassas na literatura. Além disso, o possível envolvimento da ação antioxidante no seu efeito neuroprotetor, e sobre a atividade de enzimas importantes do Sistema Nervoso Central (como a Na+/K+-ATPase e a monoamina oxidase - MAO), ainda não foi completamente elucidado. Portanto, o objetivo deste estudo foi investigar o efeito da silimarina na atividade das enzimas Na+/K+-ATPase e MAO bem como a sua capacidade de modular a ação de antimicrobianos in vitro. Os resultados demonstraram que a silimarina sequestrou o radical DPPH (2,2-difenil-1-picrilidrazina) e também reduziu significativamente a peroxidação lipídica em homogeneizado de cérebro de ratos induzida por nitroprussiato de sódio (5 M) e Fe+2 (10 M). A silimarina protegeu contra a oxidação dos grupos tióis proteicos (e não proteicos) induzida pelos pró-oxidantes e evitou a diminuição na atividade da catalase causada pelos pró-oxidantes, na concentração de 30 g/mL. A incubação de diferentes concentrações de silimarina aumentou a atividade da enzima Na+/K+-ATPase e reduziu a atividade das enzimas MAO-A e MAO-B. No entanto, a inibição da MAO-B foi mais pronunciada. A avaliação dos parâmetros cinéticos demonstrou que a silimarina não alterou de forma significativa os valores de Km para a MAO-A e MAO-B, mas causou diminuição nos valores de Vmax para as duas isoformas da enzima. No que diz respeito à atividade antimicrobiana, a silimarina e o seu principal componente ativo, a silibinina, não demonstraram atividade antibacteriana e antifúngica clinicamente relevante (com valores de CIM - concentração inibitória mínima superiores a 500 μg/mL). No entanto, a silibinina apresentou atividade antibacteriana clinicamente significativa contra Escherichia coli com CIM/8 de 64 μg/mL. A combinação de silibinina ou silimarina demonstrou efeito sinérgico modulando a eficácia de fármacos antibióticos (amicacina, gentamicina, ciprofloxaxino ou imipenem) ou antifúngicos (mebendazol ou nistatina) particularmente da classe dos aminoglicosídeos, contra as cepas multirresistentes de E. coli, Pseudomonas aeruginosa e Staphylococcus aureus. No entanto, a silibinina antagonizou o efeito antibacteriano da gentamicina e do imipenem contra P. aeruginosa. Da mesma forma, a silimarina e a silibinina tiveram efeito antagônico com a nistatina contra Candida albicans, Candida tropicalis e Candida kruzei. Em conclusão, os resultados mostraram que a silimarina altera as atividades da Na+/K+-ATPase e MAO, indicando que o seu efeito neuroprotetor não está apenas associado à sua capacidade antioxidante. O potencial da silimarina e da silibinina para modular o efeito de fármacos antimicrobianos sugere uma alternativa para o controle das infecções bacterianas provocadas pela resistência aos antibióticos.

L'infection par le virus de l'hépatite C (VHC) est un problème de santé publique majeur car en absence de vaccin et de thérapie suffisamment efficace, l’infection peut dégénérer en carcinome hépatocellulaire. Il est alors important d’identifier de nouvelles cibles thérapeutiques et de développer de nouveaux antiviraux. Ainsi, nous avons étudié l'activité anti-VHC de différents composés : l'arbidol (Arb), la silymarine (SM) et les molécules la composant, notamment la silibinine (SbN). Ces composés ont l'avantage d'être déjà utilisés en médecine humaine depuis de nombreuses années et ont ainsi prouvé leur innocuité. Ils présentent un large spectre antiviral et inhibent plusieurs étapes du cycle viral, dont la fusion membranaire. Cette étape du cycle est intéressante à cibler car le virus serait bloqué précocement, avant de provoquer des dommages cellulaires.Nous avons approfondi notre connaissance du mécanisme d'inhibition de la fusion par Arb en montrant par différentes stratégies qu'il s'associe avec les phospholipides à l'interface membranaire et interagit avec des résidus aromatiques. Cela suggère que Arb pourrait former durant le processus de fusion un complexe entre glycoprotéine virale et membrane, permettant d'inhiber les changements conformationnels de la glycoprotéine, nécessaires à la fusion. De même SM et ses composés inhibent la fusion de pseudoparticules de HCV, probablement en stabilisant les membranes impliquées dans le processus. Enfin, nous avons observé une activité antivirale et anti-inflammatoire très différente entre deux formulations de SbN. Tous ces résultats sont discutés dans le contexte actuel d'un arsenal thérapeutique anti-HCV qui reste limité<br>Infection by the hepatitis C virus (HCV) is a major public health problem since the infection can lead to hepatocellular carcinoma in the current absence of vaccine and effective treatment. It is therefore important to identify new therapeutic targets and to develop novel antiviral drugs. Here we studied the anti-HCV activity of two compounds : arbidol (Arb), the herbal extract silymarin (SM) and molecules therein, including silibinin (SbN). These compounds are already in use in human medicine for several years and have proven safety. They display a broad antiviral spectrum and inhibit several steps of the virus life cycle, including membrane fusion. This step is very interesting to target, since the virus could be blocked upstream the cellular damages it could induce. Using different biophysical strategies, we showed that Arb associates with phospholipids at the membrane interface and interacts with aromatic residues. This suggests that Arb could form during the fusion process a complex between viral glycoprotein(s) and membrane, leading to the inhibition of the conformational changes within the glycoprotein that are required during the fusion process. SM and its components inhibit fusion of HCV pseudoparticles, probably by stabilizing the membranes involved in this process. Finally, we observed different antiviral and anti-inflammatory activities between two different formulations of SbN. Knowledge of these antiviral mechanisms should lead to innovative therapeutic strategies against HCV

碩士<br>國立陽明大學<br>傳統醫藥學研究所<br>97<br>Silymarin, one of the most popular herbal medicines, has been widely used for its hepatoprotective effects. The aim of this study is to investigate the effects of silymarin and its major ingredient silibinin on the pharmacokinetics of the antidepressant trazodone. Male Sprague-Dawley rats were randomly divided into six groups in a parallel design as follows: one group treated single-dose silymarin (1.0 g/kg) 4 h prior to the administration of trazodone, the control group treated with vehicle, two groups pretreated with 0.175 and 0.35 g/kg/day silibinin and another two groups treated with 0.5 and 1.0 g/kg/day silymarin for 7 consecutive days. A microdialysis coupled with high performance liquid chromatography system (HPLC) was used to simultaneously monitor blood and bile concentrations of trazodone in rats. The results indicate that pretreatment with 1.0 g/kg/day silymarin significantly decreases trazodone’s area under the concentration curve (AUC) by 43%, distribution half-life (t1/2,α) by 52%, elimination half-life (t1/2,ß) by 31%, and mean residence time (MRT) by 44%. In contrast, the clearance (Cl) is markedly increased by 61%. In addition, single-dose silymarin (1.0 g/kg) significantly decreased the AUC of trazodone in bile by 49% when compared with the control group. The results revealed that 7-day silymarin treatments might result in enhanced cytochrome P450 expression, which facilitated the metabolism of trazodone. Single-dose silymarin treatments might lead to the inhibition of transporter, which suppressed the bile excretion of trazodone. In conclusion, the present study points out a potential herb-drug interaction between long-term silymarin ingestion and trazodone.

The global incidence of type 1 diabetes mellitus (T1DM) is rising substantially and T1DM remains a marked economic burden despite advances in the diagnosis, prevention, and treatment of complications. T1DM, often associated with autoimmune disease, is characterized by insulin deficiency and insufficiency due to beta cell destruction. The primary treatment for T1DM is insulin therapy, limited by the risk of hypoglycemia and weight gain. Other treatments for T1DM are teplizumab and donislecel, which have recently received FDA approval. Beyond these treatment options, T1DM patients are interested in non-pharmacological interventions and are willing to use herbal products. Therefore, we reviewed the effects of herbal medicines used for T1DM, including fenugreek, ficus extracts, cinnamon, berberine, silymarin, silibinin, curcumin, resveratrol, catechins, ginseng, olive leaf, allicin, thymoquinone, and mangiferin to understand their level of evidence and associated effects, and their potential for use as antidiabetic agents in the clinic. As a result of our research, the majority of the studies were conducted on diabetic animal models. There are limited clinical studies investigating herbal medicines in T1DM. Studies show that the abovementioned herbal medicines are beneficial in T1DM by lowering glucose levels, increasing insulin levels, and exerting anti-oxidant, anti-inflammatory, and pancreas islet β-cell protective mechanisms. However, these studies are insufficient to recommend the use of existing herbs in treating T1DM on a clinical level.